Vital Signs - Drug-resistant Pathogens and the Roles for Clinical Diagnostics

 


This issue of Vital Signs, released on June 18, 2007, provides a strategic overview of opportunities for clinical diagnostics to provide screening solutions against MDROs. Additionally, an emerging company profile is provided for Cepheid, a developer of rapid molecular diagnostics. Reimbursement and regulatory news from the FDA is also provided for June 4 - June 8, 2007.

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

Table of Contents

Vital Signs - Drug-resistant Pathogens and the Roles for Clinical DiagnosticsVital Signs: 18 June 2007This week's issue:




Related Research

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.